GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » Quick Ratio

Kindred Biosciences (Kindred Biosciences) Quick Ratio : 7.02 (As of Jun. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Kindred Biosciences's quick ratio for the quarter that ended in Jun. 2021 was 7.02.

Kindred Biosciences has a quick ratio of 7.02. It generally indicates good short-term financial strength.

The historical rank and industry rank for Kindred Biosciences's Quick Ratio or its related term are showing as below:

KIN' s Quick Ratio Range Over the Past 10 Years
Min: 5.04   Med: 16.39   Max: 45.03
Current: 7.02

During the past 9 years, Kindred Biosciences's highest Quick Ratio was 45.03. The lowest was 5.04. And the median was 16.39.

KIN's Quick Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.33 vs KIN: 7.02

Kindred Biosciences Quick Ratio Historical Data

The historical data trend for Kindred Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindred Biosciences Quick Ratio Chart

Kindred Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 15.01 13.58 5.04 7.35 9.05

Kindred Biosciences Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.42 12.64 9.05 12.07 7.02

Competitive Comparison of Kindred Biosciences's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kindred Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindred Biosciences's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kindred Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Kindred Biosciences's Quick Ratio falls into.



Kindred Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Kindred Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Quick Ratio (A: Dec. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(62.624-0.207)/6.896
=9.05

Kindred Biosciences's Quick Ratio for the quarter that ended in Jun. 2021 is calculated as

Quick Ratio (Q: Jun. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(79.083-0)/11.26
=7.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kindred Biosciences  (NAS:KIN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Kindred Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindred Biosciences (Kindred Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010
Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.
Executives
Richard Chin director, officer: Chief Executive Officer C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee officer: Chief Financial Officer C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan officer: Chief Scientific Officer C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery director C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof officer: SVP of Regulatory Affairs C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley officer: Chief Commercial Officer C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker officer: Chief Financial Officer 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz officer: Chief Scientific Officer C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010